Catalyst Pharmaceuticals, Inc. Forecast, price target & analysts
Catalyst Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
Catalyst Pharmaceuticals, Inc. Classifications & Recommendation:
Catalyst Pharmaceuticals, Inc. Price Target
| Target Price | $34.68 |
| Price | $23.15 |
| Potential |
49.81%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Catalyst Pharmaceuticals, Inc. 2027 .
The average Catalyst Pharmaceuticals, Inc. target price is $34.68.
This is
49.81%
register free of charge
$42.00
81.43%
register free of charge
$32.32
39.61%
register free of charge
|
|
| A rating was issued by 14 analysts: 13 Analysts recommend Catalyst Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Catalyst Pharmaceuticals, Inc. stock has an average upside potential 2027 of
49.81%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 491.73 | 589.43 |
| 23.49% | 19.87% | |
| EBITDA Margin | 47.28% | 56.01% |
| 57.71% | 18.46% | |
| Net Margin | 33.33% | 33.66% |
| 85.85% | 0.99% |
10 Analysts have issued a sales forecast Catalyst Pharmaceuticals, Inc. 2025 . The average Catalyst Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Catalyst Pharmaceuticals, Inc. EBITDA forecast 2025. The average Catalyst Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Catalyst Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Catalyst Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 1.31 | 1.61 |
| 107.94% | 22.90% | |
| P/E | 14.38 | |
| EV/Sales | 3.66 |
10 Analysts have issued a Catalyst Pharmaceuticals, Inc. forecast for earnings per share. The average Catalyst Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Catalyst Pharmaceuticals, Inc....
Current Catalyst Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citigroup |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| Baird |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
| Baird |
Locked
➜
Locked
|
Locked | Feb 04 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Jan 09 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citigroup:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
Baird:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Feb 27 2025 |
|
Locked
Baird:
Locked
➜
Locked
|
Feb 04 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 10 2025 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Jan 09 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
